Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion

Kazuhiko Kurozumi, Kentaro Fujii, Kana Washio, Joji Ishida, Yoshihiro Otani, Tamotsu Sudo, Makoto Tahara, Koichi Ichimura, Daisuke Ennishi, Isao Date

Research output: Contribution to journalArticlepeer-review

Abstract

Glioneuronal tumor (GNT) is a rare tumor. We previously reported a case of high-grade GNT with Rho/Rac guanine nucleotide factor 2 (ARHGEF2)-neurotrophic tropomyosin receptor kinase (NTRK)1 fusion and emphasized the importance of complementary molecular analysis.1 MRI at follow-up showed tumor progression. A cancer gene panel test was performed, and the presence of the ARHGEF2-NTRK1 fusion gene was confirmed. Treatment with entrectinib, an inhibitor of NTRK, was started. MRI follow-ups revealed dramatic responses. However, the patient reported severe general fatigue, and the dose was decreased following the reduced drug protocol. This case highlights the necessity of determining an optimal dose and further profiling the side effects of NTRK inhibitors.

Original languageEnglish
Article numbervdac094
JournalNeuro-Oncology Advances
Volume4
Issue number1
DOIs
Publication statusPublished - Jan 1 2022

ASJC Scopus subject areas

  • Clinical Neurology
  • Oncology
  • Surgery

Fingerprint

Dive into the research topics of 'Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion'. Together they form a unique fingerprint.

Cite this